203,006 Shares in Oric Pharmaceuticals, Inc. $ORIC Bought by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC acquired 203,006 shares of Oric Pharmaceuticals valued at approximately $1.13 million, representing a 0.29% stake in the company.
• Several institutional investors, including Bank of America and Vivo Capital, have raised their stakes in Oric Pharmaceuticals, indicating strong institutional interest.
• Oric Pharmaceuticals reported a quarterly earnings loss of ($0.47) per share, missing analysts' estimates by ($0.01), and analysts forecast an average EPS of -2.17 for the current fiscal year.

Parkman Healthcare Partners LLC acquired a new stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 203,006 shares of the company's stock, valued at approximately $1,133,000. Parkman Healthcare Partners LLC owned about 0.29% of Oric Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Oric Pharmaceuticals by 34.0% during the fourth quarter. Bank of America Corp DE now owns 112,520 shares of the company's stock valued at $908,000 after acquiring an additional 28,570 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Oric Pharmaceuticals by 16.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock valued at $5,788,000 after acquiring an additional 103,237 shares during the last quarter. Vivo Capital LLC raised its stake in shares of Oric Pharmaceuticals by 62.8% during the first quarter. Vivo Capital LLC now owns 2,080,450 shares of the company's stock valued at $11,609,000 after acquiring an additional 802,632 shares during the last quarter. Sphera Funds Management LTD. raised its stake in Oric Pharmaceuticals by 112.8% in the fourth quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company's stock worth $2,205,000 after buying an additional 144,817 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in Oric Pharmaceuticals by 14.3% in the fourth quarter. Two Sigma Advisers LP now owns 66,500 shares of the company's stock worth $537,000 after buying an additional 8,300 shares in the last quarter. 95.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. HC Wainwright decreased their price target on shares of Oric Pharmaceuticals from $22.00 to $19.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. LADENBURG THALM/SH SH assumed coverage on shares of Oric Pharmaceuticals in a research note on Tuesday, July 8th. They issued a "buy" rating and a $15.00 price target for the company. Guggenheim assumed coverage on shares of Oric Pharmaceuticals in a research note on Thursday. They issued a "buy" rating and a $18.00 price target for the company. Zacks Research raised shares of Oric Pharmaceuticals to a "hold" rating in a research note on Tuesday, August 12th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.29.

Insider Activity at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 32,466 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total value of $340,893.00. Following the sale, the chief financial officer owned 68,317 shares in the company, valued at approximately $717,328.50. This trade represents a 32.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Angie You bought 26,597 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was bought at an average price of $9.39 per share, for a total transaction of $249,745.83. Following the acquisition, the director directly owned 26,597 shares of the company's stock, valued at $249,745.83. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 37,400 shares of company stock worth $390,263 in the last 90 days. 6.82% of the stock is currently owned by corporate insiders.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $10.88 on Friday. Oric Pharmaceuticals, Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The company has a 50 day simple moving average of $10.41 and a two-hundred day simple moving average of $8.08. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.76 and a beta of 1.63.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). On average, analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.